NSRX Nasus Pharma Ltd.
$3.34▲ +0.60%
Healthcare
Other
Volume 5.4K
Avg Volume (10D) 21.2K
Key Metrics & Fundamentals
Market Cap
$39.12M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.98 - 9.50
% vs 50 MA
-7.43%
% vs 200 MA
-9.32%
RSI-14
46.7
MACD Histogram
+0.0100
Beta (1Y vs SPY)
0.73
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
GlobeNewswire · Sep 29, 2026 8:00 AM ET
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
GlobeNewswire · Sep 14, 2026 8:00 AM ET
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 7:30 AM ET
Nasus Pharma Files $50 Million Shelf Registration
MT Newswires · Sep 1, 2026 5:56 PM ET
NSRX: First Half 2026 Financial Results
Zacks Small Cap Research · Aug 21, 2026 7:00 AM ET
NSRX: First Half 2026 Financial Results
Zacks Small Cap Research · Aug 21, 2026 7:00 AM ET
Nasus Pharma Announces Transition of Chief Financial Officer
GlobeNewswire · Aug 19, 2026 7:00 AM ET
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 17, 2026 8:14 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.